Neuromelanin of the substantia nigra: A neuronal black hole with protective and toxic characteristics

Trends in Neurosciences

Volumn 26, Issue 11, 2003, Pages 578-580

  Zecca, Luigi ^a   Zucca, Fabio A ^a   Wilms, Henrik ^b   Sulzer, David ^c  

^a Institute of Biomedical Technologies   (Italy)

^b UNIVERSITY OF KIEL   (Germany)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATECHOL DERIVATIVE; MELANIN; METAL; NEUROMELANIN; PESTICIDE; PIGMENT; SCAVENGER; TOXIN;

AGING; BIOSYNTHESIS; CELL LOSS; CHEMICAL STRUCTURE; CHRONIC INFLAMMATION; CYTOSOL; DOPAMINERGIC NERVE CELL; HUMAN; METAL BINDING; MOLECULAR INTERACTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0242285663     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2003.08.009     Document Type: Short Survey

References (37)

1. Graham D.G. On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 103:1979;359-362.
2. Cotzias G.C., et al. Melanogenesis and extrapiramidal diseases. Fed. Proc. 23:1964;713-718.
3. Marsden C.D. Pigmentation in the nucleus substantiae nigrae of mammals. J. Anat. 95:1961;256-261.
4. Cozzi B., Tozzi F. A spectroscopy study of the equine brain melanins. Archo. Vet. It. (Milano). 36:1985;34-40.
5. Duffy P.E., Tennyson V.M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J. Neuropathol. Exp. Neurol. 24:1965;398-414.
6. Kastner A., et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59:1992;1080-1089.
7. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
8. Odh G., et al. Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62:1994;2030-2036.
9. Wakamatsu K., et al. The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86:2003;1015-1023.
10. Zecca L., et al. Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 74:2000;1758-1765.
11. Bridelli M.G., et al. The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett. 457:1999;18-22.
12. Double K.L., et al. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75:2000;2583-2589.
13. Zecca L., et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience. 73:1996;407-415.
14. Xu Y., et al. Tyrosinase mRNA is expressed in human substantia nigra. Brain Res. Mol. Brain Res. 45:1997;159-162.
15. Tief K., et al. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res. Mol. Brain Res. 53:1998;307-310.
16. Ikemoto K., et al. Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci. Lett. 253:1998;198-200.
17. Foley J.M., Baxter D. On the nature of pigment granules in the cell of the locus coeruleus and substantia nigra. J. Neuropathol. Exp. Neurol. 17:1958;586-598.
18. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
19. Matsunaga J., et al. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. 274:1999;3268-3271.
20. Fornstedt B., et al. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology. 25:1986;451-454.
21. Sulzer D., et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 97:2000;11869-11874.
22. D'Amato R.J., et al. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science. 231:1986;987-989.
23. 14C diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93:1988;1-6.
24. Salazar M., et al. Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed. Proc. 37:1978;2403-2407.
25. Zecca L., et al. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62:1994;1097-1101.
26. Good P.F., et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593:1992;343-346.
27. Jellinger K., et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59:1992;1168-1171.
28. Zareba M., et al. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta. 1271:1995;343-348.
29. Zecca L., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76:2001;1766-1773.
30. Lopiano L., et al. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta. 1500:2000;306-312.
31. Shima T., et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 23:1997;110-119.
32. DeMattei M., et al. Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci. Lett. 72:1986;37-42.
33. Fenichel G.M., Bazelon M. Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology. 18:1968;817-820.
34. Zecca L., et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510:2002;216-220.
35. McGeer P.L., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
36. Langston J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine exposure. Ann. Neurol. 46:1999;598-605.
37. Wilms H., et al. Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 17:2003;500-502.